A conversation with biotech leader, Sujal Shah, former CEO of CymaBay Therapeutics about his company's story arc, leadership, resilience, and building a biotech company in the face of adversity.
Given your interest in Biotech/Pharma, you might enjoy my recent biotech piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme-based biomanufacturing platform that converts biofeedstocks into targeted chemical products.
Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential
Hey mate!
Given your interest in Biotech/Pharma, you might enjoy my recent biotech piece on eXoZymes Inc. They’ve just commercially launched a cell-free enzyme-based biomanufacturing platform that converts biofeedstocks into targeted chemical products.
Plus they just announced their first subsidary which synthesises N-trans-caffeoyltyramine (NCT) to treat MASLD/MASH. Very very interesting compound that has immense potential
https://www.slack-capital.com/p/exozymes-research-report
Thanks for sharing this, James. I’ll check it out. Hope you enjoyed our convo with Sujal.
🤙🏽🤙🏽 if you were interested in doing a pod with the team, I can connect you with the VP of Comms